The information on this website is intended for healthcare
professionals only and is provided for the purpose of scientific exchange.
The website is not country specific and may therefore contain
information that is not applicable in your country, thus you may find
information concerning study drugs or therapeutic uses that have not
been approved by drug regulatory agencies. This website is not
intended to promote in any way, any use, either approved, or
unapproved, of a Novo Nordisk product or of any other product or serve
as basis for any treatment decision or action. Please always refer to
Summary of Product Characteristics (product label) as approved by
regulatory authorities in your country or contact Novo Nordisk for
Furthermore, the site is not intended to replace the advice of a
healthcare professional and should not be construed as providing
advice or making a recommendation. Only a physician can determine
whether a specific product is correct for a particular patient. Novo
Nordisk accepts no liability for the accuracy, completeness or use of
this information, and disclaims any liability to update the
information contained on this site.
By accessing this website you accept this legal notice and expressly
confirm your status as a healthcare professional.
ADA 2021 June 25 - 29
Use of glucose-lowering agents according to cardiovascular risk factors in people With T2D and with or without CVD in the CAPTURE study
Guillermo Dieuzeide1; Abdullah Alguwaihes2; Jose Luis Arenas Leon3; Fahri Bayram4; Patrice Darmon5; Timothy Davis6; Kirsten T Eriksen7; Tianpei Hong8; Thomas J Jensen7; Csaba Lengyel9; Ofri Mosenzon10; Giuseppina T. Russo11; Shinichiro Shirabe12; Katerina Urbancova13; Sergio Vencio14; Gourav Yadav15;
1 Centro de Atención Integral en Diabetes, Endocrinología y Metabolismo Chacabuco, Buenos Aires, Argentina; 2 King Saud University, King Saud University Medical City, Riyadh, Saudi Arabia; 3 Centro de Atención e Investigación Cardiovascular del Potosí, San Luis Potosi, Mexico; 4 Erciyes University, Kayseri, Turkey; 5 Hôpital de la Conception, Marseille, France; 6 University of Western Australia, Fremantle Hospital, Fremantle, Australia; 7 Novo Nordisk A/S, Søborg, Denmark; 8 Peking University Third Hospital, Beijing, China; 9 University of Szeged, Szeged, Hungary; 10 Faculty of Medicine, Hebrew University of Jerusalem; Diabetes Unit, Department of endocrinology and metabolism, Hadassah Medical Center, Jerusalem, Israel; 11 University Hospital, Messina, Italy; 12 H. E. C Science Clinic, Yokohama, Japan; 13 Diabetologická Interní Ambulance s.r.o, Ostrava, Czech Republic; 14 Instituto de Ciencias Farmaceuticas, Goias, Brazil; 15 Global Medical Affairs, Novo Nordisk, Bangalore, India;